Nanoform Finland Oyj Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Nanoform Finland Oyj şirketinin toplam hissedar öz sermayesi €65.6M ve toplam borcu €0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €76.7M ve €11.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranı	n/a
Nakit	€46.20m
Eşitlik	€65.57m
Toplam yükümlülükler	€11.10m
Toplam varlıklar	€76.67m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4YL 'nin kısa vadeli varlıkları ( €48.5M ) kısa vadeli yükümlülüklerini ( €6.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4YL şirketinin kısa vadeli varlıkları ( €48.5M ) uzun vadeli yükümlülüklerini ( €4.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4YL borçsuzdur.

Borcun Azaltılması: 4YL şirketinin 5 yıl önce borç/öz sermaye oranı 9% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4YL şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 4YL, serbest nakit akışı her yıl % 16.9 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

Nanoform Finland Oyj Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Second quarter 2024 earnings released: €0.06 loss per share (vs €0.09 loss in 2Q 2023)

First quarter 2024 earnings released: €0.09 loss per share (vs €0.06 loss in 1Q 2023)

New minor risk - Shareholder dilution

Nanoform Finland Oyj has filed a Follow-on Equity Offering.

No longer forecast to breakeven

Full year 2023 earnings released: €0.26 loss per share (vs €0.29 loss in FY 2022)

New minor risk - Profitability

Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation

New minor risk - Share price stability

Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

Forecast to breakeven in 2026

Nanoform Finland Oyj to Report Nine Months, 2024 Results on Nov 22, 2024

Third quarter 2023 earnings released: €0.05 loss per share (vs €0.07 loss in 3Q 2022)

No longer forecast to breakeven

First quarter 2023 earnings released: €0.06 loss per share (vs €0.07 loss in 1Q 2022)

Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate

Forecast to breakeven in 2025

Nanoform Finland Oyj CTO Niklas Sandler Transitions to Technology Advisor to the CEO, effective, January 1, 2023

Nanoform Finland Oyj to Report Q3, 2023 Results on Nov 22, 2023

Nanoform Finland Oyj, Annual General Meeting, Apr 12, 2023

Third quarter 2022 earnings released: €0.07 loss per share (vs €0.06 loss in 3Q 2021)

Second quarter 2022 earnings released: €0.08 loss per share (vs €0.07 loss in 2Q 2021)

Nanoform's Gonçalo Andrade Steps Down as Chief of Business Operations

First quarter 2022 earnings released: €0.07 loss per share (vs €0.06 loss in 1Q 2021)

Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers

Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nanoform signs GMP manufacturing program with TargTex following formulation success

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Second quarter 2021 earnings released: €0.07 loss per share (vs €0.14 loss in 2Q 2020)

First quarter 2021 earnings released: €0.06 loss per share (vs €0.12 loss in 1Q 2020)

Director has left the company

Nanoform Announces Completion and Final Results of Clinical Study

Nanoform Finland Oyj has completed a Follow-on Equity Offering in the amount of €40.000001 million.

Nanoform Finland Oyj to Report Q1, 2021 Results on May 27, 2021

Nanoform Finland Announces Further Positive Interim Results from Its Ongoing Clinical Study

New 90-day high: €7.62

New 90-day high: €7.61

Nanoform's Clinical Study Indicates Positive Interim Results

New 90-day high: €6.90

Nanoform Finland plc Announces First Dosing of Nanoformed Drug Successfully Accomplished

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

New 90-day high: €4.54

Nanoform Launches Technology for Biologics and Sets New Near-Term Business Target for 2021

Nanoform Finland Oyj to Report Q3, 2020 Results on Nov 27, 2020

New 90-day low: €3.93

First half earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin